Latest News & Updates
Stay informed with OncoBeta’s latest announcements, including press releases, company updates, and key developments. This section provides timely insights into our activities, partnerships, and progress in advancing radiopharmaceutical innovation.
OncoBeta Takes Notable Strides Forward in 2024
OncoBeta® has made notable strides in combating non-melanoma skin cancers (NMSCs), with its therapy, Rhenium-SCT® (skin cancer therapy), which utilises rhenium-188 for targeted, non-invasive treatment. Over the past year, the company has delivered more studies to the growing body of evidence, pursued further regulatory approvals, and focused on patient education, while also raising global awareness, […]
OncoBeta reports 12-Month Results from International Phase IV Study for Non-Melanoma Skin Cancer
OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, has announced 12-months interim results from its international Phase IV, multi-centre clinical trial evaluating the efficacy and safety of Rhenium-SCT® (Skin Cancer Therapy) in patients with non-melanoma skin cancer (NMSC). The EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT for the Treatment of […]
Explore More
Stay connected with the latest developments in Rhenium-SCT by learning more about who we are and what we do. Visit the About Us page to understand our mission and approach, explore the Patients section for information on treatment and care, or access the HCP resources for clinical information and professional guidance.